Advanced glycation end products (AGEs) and the soluble receptor for AGE (sRAGE) in patients with type 1 diabetes and coeliac disease

被引:22
作者
Bakker, S. F. [1 ]
Tushuizen, M. E. [1 ]
Gozutok, E. [2 ]
Ciftci, A. [2 ]
Gelderman, K. A. [3 ]
Mulder, C. J. [1 ]
Simsek, S. [2 ,4 ]
机构
[1] Vrije Univ Amsterdam, Med Ctr, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands
[2] Med Ctr Alkmaar, Dept Internal Med, NL-1815 JD Alkmaar, Netherlands
[3] Vrije Univ Amsterdam, Med Ctr, Dept Med Immunol, Amsterdam, Netherlands
[4] Vrije Univ Amsterdam, Med Ctr, Dept Internal Med, Amsterdam, Netherlands
关键词
Advanced glycation end products; AGE; Autofluorescence; Coeliac disease; Gluten-free diet; Soluble receptor-AGE; Type; 1; diabetes; GLUTEN-FREE DIET; SKIN AUTOFLUORESCENCE; MICROVASCULAR COMPLICATIONS; INCREASED ACCUMULATION; RISK-FACTOR; MELLITUS; GLYCOTOXINS; DYSFUNCTION; PREDICTOR; MORTALITY;
D O I
10.1016/j.numecd.2014.10.009
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background and aims: Advanced glycation end (AGE) products play a role in the progression of diabetic complications. Gluten-free diet (GFD) might affect AGE levels in patients who adhere to a GFD because of coeliac disease (CD). The aim of our study was to compare skin AGE levels and soluble receptor AGE levels (sRAGE) in patients with type 1 diabetes (T1DM) with (T1DM + CD) and without CD (T1DM - CD) and healthy controls. Methods and results: We recruited 25 T1DM + CD and 25 T1DM e CD patients, matched for age, gender, diabetes duration, and glycaemic control alongside 25 healthy controls. We collected demographic, clinical and biochemical characteristics, including skin autofluorescence (AF), sRAGE and hs-CRP levels. The duration of T1DM in patients was 30 +/- 14 (+CD) and 29 +/- 14 years (-CD), whereas CD duration in T1DM + CD patients was 14 +/- 10 years. Skin AF levels in T1DM patients were higher compared to healthy controls (2.5 +/- 0.6 versus 1.9 +/- 0.4, p < 0.01) and skin AF was independently associated with age (r = 0.72, p < 0.01). sRAGE levels were higher in T1DM - CD patients compared to healthy controls (1554 +/- 449 versus 1309 +/- 400, p = 0.049) and independently associated with creatinine levels (r = 0.32, p < 0.01). Conclusion: Our study demonstrates that skin AGE and sRAGE levels are elevated in T1DM patients compared with healthy controls. No difference in skin AF or sRAGE levels between T1DM patients with or without CD were observed. The present study suggests that differences in microvascular complications between T1DM and T1DM + CD patients are not due to differences in skin AF or sRAGE levels. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:230 / 235
页数:6
相关论文
共 30 条
[1]
Integration of Genetic and Immunological Insights into a Model of Celiac Disease Pathogenesis [J].
Abadie, Valerie ;
Sollid, Ludvig M. ;
Barreiro, Luis B. ;
Jabri, Bana .
ANNUAL REVIEW OF IMMUNOLOGY, VOL 29, 2011, 29 :493-525
[2]
[Anonymous], DIABETES CARE S1
[3]
Increased Accumulation of Skin Advanced Glycation End Products Is Associated with Microvascular Complications in Type 1 Diabetes [J].
Araszkiewicz, Aleksandra ;
Naskret, Dariusz ;
Niedzwiecki, Pawel ;
Samborski, Pawel ;
Wierusz-Wysocka, Bogna ;
Zozulinska-Ziolkiewicz, Dorota .
DIABETES TECHNOLOGY & THERAPEUTICS, 2011, 13 (08) :837-842
[4]
Type 1 diabetes and celiac disease in adults: glycemic control and diabetic complications [J].
Bakker, Sjoerd F. ;
Tushuizen, Maarten E. ;
von Blomberg, Mary E. ;
Mulder, Chris J. ;
Simsek, Suat .
ACTA DIABETOLOGICA, 2013, 50 (03) :319-324
[5]
Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications [J].
Bierhaus, A. ;
Nawroth, P. P. .
DIABETOLOGIA, 2009, 52 (11) :2251-2263
[6]
AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: A "glycoxidation-centric" point of view [J].
Chilelli, N. C. ;
Burlina, S. ;
Lapolla, A. .
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2013, 23 (10) :913-919
[7]
Childhood coeliac disease: towards an improved serological mass screening strategy [J].
Esch, C. E. Hogen ;
Csizmadia, G. D. S. ;
Van Hoogstraten, I. M. W. ;
Schreurs, M. W. J. ;
Mearin, M. L. ;
Von Blomberg, B. M. E. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 31 (07) :760-766
[8]
Coeliac disease, gluten-free diet and the development and progression of albuminuria in children with type 1 diabetes [J].
Gopee, Esha ;
van den Oever, Eva L. M. ;
Cameron, Fergus ;
Thomas, Merlin C. .
PEDIATRIC DIABETES, 2013, 14 (06) :455-458
[9]
Coeliac disease and Type 1 diabetes mellitus - the case for screening [J].
Holmes, GKT .
DIABETIC MEDICINE, 2001, 18 (03) :169-177
[10]
European Society for Pediatric Gastroenterology, Hepatology, and Nutrition Guidelines for the Diagnosis of Coeliac Disease [J].
Husby, S. ;
Koletzko, S. ;
Korponay-Szabo, I. R. ;
Mearin, M. L. ;
Phillips, A. ;
Shamir, R. ;
Troncone, R. ;
Giersiepen, K. ;
Branski, D. ;
Catassi, C. ;
Lelgeman, M. ;
Maki, M. ;
Ribes-Koninckx, C. ;
Ventura, A. ;
Zimmer, K. P. .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2012, 54 (01) :136-160